TrendingTopic

kidney disease therapeutics and safety signals

April 4, 2026ASN Publications, KIReports, NDT

ASN Publications, KIReports, NDT, NephroPOCUS, and clinicians highlight CKD guideline implementation, SGLT2 use, QT-prolonging meds in CKD, and diagnostic imaging pearls as a multi-post theme.

The dramatic expansion in CKD therapeutics to prevent progression of kidney disease
SGLT2-inhibitors in Adult Patients With #Alport Syndrome
QT-prolonging medications: prevalence of use and associated risks in CKD
Very interesting #echofirst image.
ASN Publications
KIReports
NDT
NephroPOCUS
Sam Albadri, M.D., M.Sc.
Conrad Fischer
Arkana Laboratories
European Society of Cardiology Journals
nephrologyCKDpatient-safety

See what experts are saying right now

This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.

← Back to Healthcare